Email Alert | RSS

北京大学学报（医学版） ›› 2024, Vol. 56 ›› Issue (2): 207-212. doi: 10.19723/j.issn.1671-167X.2024.02.002

• 论著 • 上一篇    下一篇

NEAT1、miR-27a-3p在阿尔茨海默病患者血清和脑脊液中的表达关系

何丽杰1,*(),张春艳2,王静1   

  1. 1. 天津市第五中心医院检验科，天津 300450
    2. 天津市第五中心医院天津市早产儿器官发育表观遗传重点实验室，天津 300450
  • 收稿日期:2023-09-18 出版日期:2024-04-18 发布日期:2024-04-10
  • 通讯作者: 何丽杰 E-mail:irfsq59@163.com
  • 基金资助:
    天津市科技计划项目(21JCZDJC01270)

Expression relationship and significance of NEAT1 and miR-27a-3p in serum and cerebrospinal fluid of patients with Alzheimer disease

Lijie HE1,*(),Chunyan ZHANG2,Jing WANG1   

  1. 1. Department of Laboratory, Tianjin Fifth Central Hospital, Tianjin 300450, China
    2. Tianjin Key Laboratory of Organ Development Epigenetics of Premature Infants, Tianjin Fifth Central Hospital, Tianjin 300450, China
  • Received:2023-09-18 Online:2024-04-18 Published:2024-04-10
  • Contact: Lijie HE E-mail:irfsq59@163.com
  • Supported by:
    the Tianjin Science and Technology Program(21JCZDJC01270)

RICH HTML

   

PDF (PC)

摘要：

目的: 探究长链非编码RNA核富含丰富的转录本1(long chain non-coding RNA nuclear-enriched abundant transcript 1，LncRNA NEAT1)、miR-27a-3p在阿尔茨海默病(Alzheimer disease，AD)患者血清和脑脊液中的表达关系及意义。方法: 选择2019年10月至2021年9月天津市第五中心医院神经内科收治的AD患者66例作为病例组，根据临床痴呆评定量表(clinical dementia rating，CDR)评分分为轻度组(≤1分，n=41)与中重度组(＞1分，n=25)；另取同期门诊其他就诊患者血清和脑脊液标本66例志愿者作为对照组。收集所有受试者的一般资料并评估认知程度，采用实时荧光定量PCR检测血清和脑脊液miR-27a-3p、NEAT1表达水平，酶联免疫吸附试验检测脑脊液β-淀粉样前体蛋白裂解酶1(β-site amyloid precursor protein cleaving enzyme 1，BACE1)、β淀粉样蛋白(amyloid β，Aβ)40和Aβ42水平，采用Spearman法分析血清miR-27a-3p、NEAT1水平与简易精神状态检测量表的相关性，采用Pearson法分析血清miR-27a-3p、NEAT1水平与Aβ沉积平均标准摄取值比率(standardized uptake value ratio，SUVR)及脑脊液miR-27a-3p、NEAT1、BACE1、Aβ42、Aβ40水平的相关性。结果: MMSE评分[21 (17，25)，9(7，11) vs. 27 (21，34)]、MoCA评分[17 (12，21)，10 (7，13) vs. 27 (21，31)]、血清miR-27a-3p水平(0.55±0.13，0.46±0.06 vs. 0.97±0.22)、脑脊液miR-27a-3p(0.48±0.10，0.35±0.10 vs. 1.03±0.31)、Aβ42水平[(303.55±36.77) ng/L，(231.45±34.14) ng/L vs.(499.99±53.63) ng/L]及Aβ42/Aβ40比值(0.030±0.008，0.022±0.007 vs. 0.048±0.010)轻度组、中重度组AD患者均低于对照组(P均＜0.05)，且中重度组AD患者较轻度组低(P均＜0.05)；血清NEAT1水平(2.31±0.64，3.13±0.76 vs. 1.05±0.20)、SUVR(1.50±0.29，1.76±0.52 vs. 0.74±0.15)及脑脊液NEAT1(3.51±1.24，4.30±1.65 vs. 1.01±0.23)、BACE1水平[(55.78±5.98) μg/L，(72.32±16.08) μg/L vs. (21.39±3.73) μg/L]轻度组、中重度组AD患者均高于对照组(P均＜0.05)，且中重度组AD患者较轻度组高(P均＜0.05)。AD患者血清NEAT1水平与SUVR及脑脊液NEAT1、BACE1呈正相关(r=0.350，0.606，0.341，P＜0.05)，与MMSE评分、MoCA评分呈负相关(r=-0.473，-0.482，P均＜0.05)；血清miR-27a-3p水平与脑脊液miR-27a-3p水平、MMSE评分、MoCA评分呈正相关(r=0.695，0.424，0.412，P＜0.05)，与SUVR及脑脊液BACE1水平呈负相关(r=-0.521、-0.447，P均＜0.05)。结论: NEAT1、miR-27a-3p在AD患者血清及脑脊液中表达趋势具有一致性，NEAT1水平均升高，miR-27a-3p水平均降低，二者水平呈负相关，与AD患者脑中Aβ沉积程度有关，并参与AD的病情进展。

关键词: 阿尔茨海默病, 长链非编码RNA核富含丰富的转录本1, miR-27a-3p, β淀粉样蛋白, 相关性

Abstract:

Objective: To explore the expression relationship and significance of long chain non-coding RNA nuclear-enriched abundant transcript 1 (LncRNA NEAT1) and miR-27a-3p in serum and cerebrospinal fluid of patients with Alzheimer disease (AD). Methods: Sixty-six AD patients received by the department of neurology of our hospital from October 2019 to September 2021 were gathered, according to the clinical dementia rating scale score, they were grouped into mild group (≤1 point, n=41) and moderate-to-severe group (>1 point, n=25). Another 66 cases of serum and cerebrospinal fluid samples from outpatient physical examination personnel were regarded as the control group. The general information on all subjects was recorded and cognition was assessed; real-time quantitative PCR was performed to measure the expression levels of miR-27a-3p and NEAT1 in serum and cerebrospinal fluid; enzyme-linked immunosorbent assay was performed to measure the protein levels of β-amyloid precursor protein cleaving enzyme 1 (BACE1), β-amyloid (Aβ) 40 and Aβ42 in cerebrospinal fluid; Spearman' s method was performed to analyze the correlation of serum miR-27a-3p and NEAT1 levels with mini-mental state examination (MMSE) and montreal cognitive assessment (MoCA) scores; Pearson method was performed to analyze the correlation between serum miR-27a-3p and NEAT1 levels and Aβ deposition standard uptake value ratio (SUVR) and cerebrospinal fluid miR-27a-3p, NEAT1, BACE1, Aβ42 and Aβ40 levels. Results: The MMSE score [21 (17, 25), 9(7, 11) vs. 27 (21, 34)], MoCA score [17 (12, 21), 10 (7, 13) vs. 27 (21, 31)], serum miR-27a-3p level (0.55±0.13, 0.46±0.06 vs. 0.97±0.22), cerebrospinal fluid miR-27a-3p (0.48±0.10, 0.35±0.10 vs. 1.03±0.31), Aβ42 levels [(303.55±36.77) ng/L, (231.45±34.14) ng/L vs. (499.99±53.63) ng/L] and Aβ42/Aβ40 ratio (0.030±0.008, 0.022±0.007 vs. 0.048±0.010) of AD patients in mild group and moderate-to-severe group were all lower than those in the control group, and the moderate-to-severe group were lower than the mild group (all P < 0.05); the serum NEAT1 level (2.31±0.64, 3.13±0.76 vs. 1.05±0.20), SUVR (1.50±0.29, 1.76±0.52 vs. 0.74±0.15), and cerebrospinal fluid NEAT1 (3.51±1.24, 4.30±1.65 vs. 1.01±0.23) and BACE1 levels [(55.78±5.98) μg/L, (72.32±16.08) μg/L vs. (21.39±3.73) μg/L] were higher than those in the control group, and the moderate-to-severe group were higher than the mild group (all P < 0.05). Serum NEAT1 level in AD patients was positively correlated with SUVR, cerebrospinal fluid NEAT1 and BACE1 (r=0.350, 0.606, 0.341, P < 0.05), and negatively correlated with MMSE score and MoCA score (r=-0.473, -0.482, all P < 0.05); serum miR-27a-3p level was positively correlated with cerebrospinal fluid miR-27a-3p level, MMSE score and MoCA score (r=0.695, 0.424, 0.412, all P < 0.05), and negatively correlated with SUVR and cerebrospinal fluid BACE1 level (r=-0.521, -0.447, all P < 0.05). Conclusion: The expression trends of NEAT1 and miR-27a-3p in the serum and cerebrospinal fluid of AD patients are consistent, the level of NEAT1 is increased, and the level of miR-27a-3p is decreased. The levels of the two are negatively correlated, which is related to the degree of Aβ deposition in the brain of AD patients and is involved in the progression of AD.

Key words: Alzheimer disease(AD), Long chain non-coding RNA nuclear-enriched abundant transcript 1 (LncRNA NEAT1), miR-27a-3p, Amyloid β (Aβ), Correlation

中图分类号: 

  • R749.16

表1

AD患者与对照组一般资料比较"

Group n Age/years, $\bar x \pm s$ Gender, male/female Educational attainment/years, $\bar x \pm s$ Alcohol, n(%) Smoking, n(%) Hypertension, n(%) Diabetes mellitus, n(%) MMSE scores, M(P25, P75) MoCA scores, M(P25, P75)
Control 66 69.45±7.36 39/27 7.65±2.13 15 (22.73) 27 (40.91) 25 (37.88) 15 (22.73) 27 (21，34) 27 (21，31)
Mild 41 71.31±7.52 23/18 7.98±2.26 9 (21.95) 19 (46.34) 13 (31.71) 7 (17.07) 21 (17，25)# 17 (12，21)#
Moderate-to- severe 25 72.57±6.83 15/10 6.92±2.05 4 (16.00) 13 (52.00) 12 (48.00) 6 (24.00) 9 (7，11)#* 10 (7，13)#*
F/χ2/H 1.914 0.128 1.894 0.510 0.967 1.752 0.627 66.379 66.553
P 0.152 0.938 0.154 0.775 0.617 0.416 0.731 < 0.001 < 0.001

表2

AD患者与对照组血清NEAT1、miR-27a-3p水平比较($\bar x \pm s$)"

Group n NEAT1/GAPDH miR-27a-3p/U6
Control 66 1.05±0.20 0.97±0.22
Mild 41 2.31±0.64# 0.55±0.13#
Moderate-to-severe 25 3.13±0.76#* 0.46±0.06#*
F 180.359 114.371
P < 0.001 < 0.001

表3

AD患者与对照组SUVR及脑脊液NEAT1、miR-27a-3p、BACE1、Aβ42、Aβ40水平比较($\bar x \pm s$)"

Group n NEAT1/GAPDH miR-27a-3p/U6 BACE1/(μg/L) Aβ40/(ng/L) Aβ42/(ng/L) SUVR Aβ42/Aβ40
Control 66 1.01±0.23 1.03±0.31 21.39±3.73 10708.99±1979.17 499.99±53.63 0.74±0.15 0.048±0.010
Mild 41 3.51±1.24# 0.48±0.10# 55.78±5.98# 10477.95±2192.92# 303.55±36.77# 1.50±0.29# 0.030±0.008#
Moderate- to-severe 25 4.30±1.65#* 0.35±0.10#* 72.32±16.08#* 11019.63±2807.62#* 231.45±34.14#* 1.76±0.52#* 0.022±0.007#*
F 132.816 113.447 444.023 0.464 415.490 144.609 98.231
P < 0.001 < 0.001 < 0.001 0.630 < 0.001 < 0.001 < 0.001

表4

AD患者血清NEAT1与SUVR、认知功能评分以及脑脊液NEAT1、BACE1、Aβ42、Aβ40水平的相关性"

Serum NEAT1 SUVR NEAT1 BACE1 Aβ42 Aβ40 MMSE scores MoCA scores
r 0.350 0.606 0.341 －0.096 －0.115 －0.473 －0.482
P < 0.001 < 0.001 0.005 0.445 0.358 < 0.001 < 0.001

表5

AD患者血清miR-27a-3p与脑脊液miR-27a-3p、BACE1、Aβ42、Aβ40水平及认知功能评分的相关性"

Serum miR-27a-3p SUVR miR-27a-3p BACE1 Aβ42 Aβ40 MMSE scores MoCA scores
r －0.521 0.695 －0.447 0.074 －0.047 0.424 0.412
P < 0.001 < 0.001 < 0.001 0.554 0.710 < 0.001 < 0.001

图1

血清(A)及脑脊液(B)NEAT1与miR-27a-3p的相关性分析"

1 Villain N , Dubois B .Alzheimer' s disease including focal presentations[J].Semin Neurol,2019,39(2):213-226.
doi: 10.1055/s-0039-1681041
2 Ossenkoppele R , Pijnenburg YA , Perry DC , et al.The behavioural/dysexecutive variant of Alzheimer' s disease: Clinical, neuroimaging and pathological features[J].Brain,2015,138(Pt 9):2732-2749.
3 Scheltens P , Blennow K , Breteler MM , et al.Alzheimer' s disease[J].Lancet,2016,388(10043):505-517.
doi: 10.1016/S0140-6736(15)01124-1
4 Serrano-Pozo A , Das S , Hyman BT .APOE and Alzheimer' s disease: Advances in genetics, pathophysiology, and therapeutic approaches[J].Lancet Neurol,2021,20(1):68-80.
doi: 10.1016/S1474-4422(20)30412-9
5 Ke S , Yang Z , Yang F , et al.Long noncoding RNA NEAT1 aggravates Aβ-induced neuronal damage by targeting miR-107 in Alzheimer' s disease[J].Yonsei Med J,2019,60(7):640-650.
doi: 10.3349/ymj.2019.60.7.640
6 Zhao MY , Wang GQ , Wang NN , et al.The long-non-coding RNA NEAT1 is a novel target for Alzheimer' s disease progression via miR-124/BACE1 axis[J].Neurol Res,2019,41(6):489-497.
doi: 10.1080/01616412.2018.1548747
7 Sala Frigerio C , Lau P , Salta E , et al.Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease[J].Neurology,2013,81(24):2103-2106.
doi: 10.1212/01.wnl.0000437306.37850.22
8 Dong LX , Zhang YY , Bao HL , et al.NEAT1 promotes Alzheimer' s disease by down regulating micro-27a-3p[J].Am J Transl Res,2021,13(8):8885-8896.
9 贾建平, 魏翠柏.2018中国痴呆与认知障碍诊治指南(二): 阿尔茨海默病诊治指南[J].中华医学杂志,2018,98(13):971-977.
doi: 10.3760/cma.j.issn.0376-2491.2018.13.004
10 贾建平, 唐毅.2018中国痴呆与认知障碍诊治指南(六): 阿尔茨海默病痴呆前阶段[J].中华医学杂志,2018,98(19):1457-1460.
doi: 10.3760/cma.j.issn.0376-2491.2018.19.001
11 Smith PY , Hernandez-Rapp J , Jolivette F , et al.miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo[J].Hum Mol Genet,2015,24(23):6721-6735.
doi: 10.1093/hmg/ddv377
12 Li QS , Cai D .Integrated miRNA-seq and mRNA-seq study to identify miRNAs associated with Alzheimer' s disease using post-mortem brain tissue samples[J].Front Neurosci,2021,15(1):620899-620913.
13 Zeng T , Ni H , Yu Y , et al.BACE1-AS prevents BACE1 mRNA degradation through the sequestration of BACE1-targeting miRNAs[J].J Chem Neuroanat,2019,98(1):87-96.
14 Yue D , Guanqun G , Jingxin L , et al.Silencing of long noncoding RNA XIST attenuated Alzheimer' s disease-related BACE1 alteration through miR-124[J].Cell Biol Int,2020,44(2):630-636.
doi: 10.1002/cbin.11263
15 Fazeli S , Motovali-Bashi M , Peymani M , et al.A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson' s patients is associated with the early stage onset of disease[J].PLoS One,2020,15(11):e0240855-e0240875.
doi: 10.1371/journal.pone.0240855
16 王锋存, 赵秀丽, 刘军莉.阿尔茨海默病患者血清LncRNA MALAT1、LncRNA NEAT1的表达变化及临床意义[J].中国现代医学杂志,2022,32(18):77-82.
17 Hampel H , Vassar R , De Strooper B , et al.The β-secretase BACE1 in Alzheimer' s disease[J].Biol Psychiatry,2021,89(8):745-756.
doi: 10.1016/j.biopsych.2020.02.001
18 Yan R , Vassar R .Targeting the β secretase BACE1 for Alzheimer' s disease therapy[J].Lancet Neurol,2014,13(3):319-329.
doi: 10.1016/S1474-4422(13)70276-X
19 Zott B , Simon MM , Hong W , et al.A vicious cycle of β amyloid-dependent neuronal hyperactivation[J].Science,2019,365(6453):559-565.
doi: 10.1126/science.aay0198
20 Nguyen LD , Chau RK , Krichevsky AM .Small molecule drugs targeting non-coding RNAs as treatments for Alzheimer's disease and related dementias[J].Genes (Basel),2021,12(12):2005-2026.
doi: 10.3390/genes12122005
[1] 赵杰, 付春, 赵秀娟, 薛海岩, 李纾, 王振洲, 朱凤雪. 胸部创伤患者在重症监护病房内发生呼吸机相关性肺炎的危险因素[J]. 北京大学学报（医学版）, 2026, 58(2): 351-358.
[2] 魏粤晖, 简伟研. 中国老年人社会经济地位与视力障碍的相关性[J]. 北京大学学报（医学版）, 2025, 57(6): 1136-1144.
[3] 丁艳, 王丽芳, 李超然, 卢哲敏, 石连杰. 利妥昔单抗成功治疗类风湿关节炎合并IgG4相关性疾病1例[J]. 北京大学学报（医学版）, 2025, 57(6): 1203-1207.
[4] 张一平, 李璐迪, 朱安, 肖武生, 王旗. 基于秀丽线虫模型探究七叶皂苷和右美沙芬对阿尔茨海默病的保护作用[J]. 北京大学学报（医学版）, 2025, 57(4): 764-771.
[5] 李奕昕, 郭煌达, 彭和香, 侯天姣, 章涵宇, 谭音希, 郑一, 王梦莹, 武轶群, 秦雪英, 李劲, 叶莺, 吴涛, 陈大方, 胡永华, 李立明. 基于家系设计的血脂指标的配偶相关性[J]. 北京大学学报（医学版）, 2025, 57(3): 423-429.
[6] 杨菊, 刘玥, 曲春娜, 孙健斌, 李天英, 石连杰. 双膦酸盐相关性颌骨坏死1例[J]. 北京大学学报（医学版）, 2025, 57(2): 388-392.
[7] 刘爱春, 赵慧萍, 武蓓, 郑姝颖, 左力, 王梅. 腹膜透析相关性腹膜炎拔管患者导管内细菌生物膜的形成[J]. 北京大学学报（医学版）, 2025, 57(1): 161-165.
[8] 刘家骏, 刘国康, 朱玉虎. 免疫相关性重症肺炎1例[J]. 北京大学学报（医学版）, 2024, 56(5): 932-937.
[9] 周颖,赵宁,黄竑远,李庆祥,郭传瑸,郭玉兴. 双层软组织缝合封闭技术在下颌骨中早期药物相关性颌骨骨坏死患者手术治疗中的应用[J]. 北京大学学报（医学版）, 2024, 56(1): 51-56.
[10] 姚中强,李常虹,李欣艺,郭苇,翟佳羽,刘蕊,魏慧,穆荣. 抗磷脂酰丝氨酸/凝血酶原抗体与不明原因复发性流产的相关性分析[J]. 北京大学学报（医学版）, 2023, 55(6): 1058-1061.
[11] 冯璐,翟佳羽,赵金霞. IgG4相关性疾病患者就诊情况及其临床特征[J]. 北京大学学报（医学版）, 2023, 55(6): 1028-1032.
[12] 冯敏,陈哲,程永静. 以十二指肠溃疡为突出表现的IgG4相关性疾病1例[J]. 北京大学学报（医学版）, 2023, 55(6): 1125-1129.
[13] 于昊哲,曾唯珍,吴文雨,姚中强,冯云. 原发性干燥综合征合并甲状腺功能减退眼表状态评估[J]. 北京大学学报（医学版）, 2022, 54(4): 705-711.
[14] 李志华,徐纯如,刘颖,贯华,张萌,车新艳,唐琦,黄燕波,李学松,周利群. 饮水习惯与上尿路尿路上皮癌病理特征的相关性分析[J]. 北京大学学报（医学版）, 2022, 54(4): 621-627.
[15] 孟广艳,张筠肖,张渝昕,刘燕鹰. IgG4相关性疾病中枢神经系统受累的临床特点分析[J]. 北京大学学报（医学版）, 2021, 53(6): 1043-1048.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部